MacroGenics, Inc. (MGNX)
Automate Your Wheel Strategy on MGNX
With Tiblio's Option Bot, you can configure your own wheel strategy including MGNX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol MGNX
- Rev/Share 2.4208
- Book/Share 1.2565
- PB 1.0107
- Debt/Equity 0.4735
- CurrentRatio 3.2844
- ROIC -0.5699
- MktCap 80124681.0
- FreeCF/Share -1.1498
- PFCF -1.1068
- PE -1.4328
- Debt/Assets 0.1668
- DivYield 0
- ROE -0.5984
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 4
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
4 Medical Product Stocks to Watch From a Challenging Industry
Published: May 21, 2025 by: Zacks Investment Research
Sentiment: Negative
The U.S. government's tariff imposition, especially on China, is likely to keep supply chains under pressure for the Zacks Medical Products industry. PODD, MGNX, CLRB and ALUR reflect the favorable fundamentals.
Read More
MacroGenics Announces Date of First Quarter 2025 Financial Results
Published: May 06, 2025 by: GlobeNewsWire
Sentiment: Neutral
ROCKVILLE, MD, May 06, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the first quarter of 2025 after the market closes on Tuesday, May 13, 2025.
Read More
4 Medical Product Stocks to Buy From a Challenging Industry
Published: April 17, 2025 by: Zacks Investment Research
Sentiment: Positive
The U.S. government's tariff imposition, especially on China, is likely to keep supply chains under pressure for the Zacks Medical Products industry. PODD, MGNX, CLRB and ALUR are likely to gain from the favorable factors.
Read More
MacroGenics: Stacking Up A Lot Of Headwinds
Published: February 27, 2025 by: Seeking Alpha
Sentiment: Neutral
MacroGenics' valuation has declined due to continued bad news in 2024, impacting market sentiment. MGNX holds $179.6M in cash and equivalents, with a sustainable cash burn rate for up to 5 years. Sale of the margetuximab franchise poises the company for further financial stability. Operating expenses are expected to rise as clinical programs advance, with management projecting a cash runway into 2026. I think this is a conservative estimate.
Read More
About MacroGenics, Inc. (MGNX)
- IPO Date 2013-10-10
- Website https://www.macrogenics.com
- Industry Biotechnology
- CEO Scott Koenig
- Employees 341